Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations. Few drug developers successfully bring a product to market. Fewer still earn multi…
Investors hoping for a revival at the struggling biotech might want to temper their expectations. Few drug developers successfully bring a product to market. Fewer still earn multi…